MDM2 and cancer: At the moment, several MDM2 inhibitors are already known, such as nutlins [63], cis-imidazole compounds (which have already been shown in clinical trials to increase intracellular p53 levels and inhibit the development of cancer cells, being promising in the treatment of lung and colon cancers), multiple myeloma (MM), and others [58].